Short Interest in Aethlon Medical, Inc. (NASDAQ:AEMD) Increases By 1,045.3%

Aethlon Medical, Inc. (NASDAQ:AEMD) saw a significant increase in short interest in May. As of May 29th, there was short interest totaling 330,345 shares, an increase of 1,045.3% from the May 14th total of 28,844 shares. Approximately 21.2% of the shares of the company are short sold. Based on an average trading volume of 3,203,228 shares, the days-to-cover ratio is currently 0.1 days.

Institutional Trading of Aethlon Medical

An institutional investor recently bought a new position in Aethlon Medical stock. Citadel Advisors LLC acquired a new stake in Aethlon Medical, Inc. (NASDAQ:AEMD) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 95,084 shares of the medical equipment provider’s stock, valued at approximately $71,000. Citadel Advisors LLC owned approximately 36.57% of Aethlon Medical at the end of the most recent reporting period. 1.99% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Aethlon Medical in a research report on Monday, April 20th. One research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Reduce”.

Aethlon Medical Trading Down 4.4%

Shares of AEMD stock opened at $1.94 on Wednesday. The stock has a 50 day moving average of $2.23 and a 200 day moving average of $2.51. The stock has a market cap of $3.05 million, a P/E ratio of -0.13 and a beta of 1.49. Aethlon Medical has a twelve month low of $1.36 and a twelve month high of $27.40.

Aethlon Medical Company Profile

Aethlon Medical, Inc (NASDAQ: AEMD) is a clinical‐stage biotechnology company focused on developing novel immunotherapeutic medical devices to address life‐threatening diseases. The company’s lead product candidate, the Hemopurifier®, is an extracorporeal affinity device designed to remove circulating viruses and immunosuppressive exosomes from the bloodstream. By targeting glycosylated pathogens and exosomes, Aethlon aims to restore immune function and improve patient outcomes in oncology and infectious disease settings.

The Hemopurifier platform leverages proprietary lectin affinity technology to selectively bind and eliminate harmful particles without depleting healthy blood components.